Session 26
Emotions and Basal ganglia derangements: a molecule-to-men approach
Programme of the Session
- S26-01
Dopamine: Neuropsychiatric Disorders and Neurotoxicity
Syed Ali1, Frederico Pereira2,3
1Neurochemistry Laboratory, Division of Neurotoxicology, National Center for Toxicological Research/FDA, Jefferson, AR, United States; 2Institute of Pharmacology and Experimental Therapeutics/IBILI, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 3CNC.IBILI, Univ. of Coimbra, Coimbra, Portugal - S26-02
The mood is in the air: environmental neurotoxicants enter the brain via olfactory system to induce depression in Parkinson’s disease
Rui Prediger
Department of Pharmacology, Universidade Federal de Santa Catarina, Florianópolis, Brazil - S26-03
Speeding and disliking: methamphetamine induces depressive-like behavior
Frederico Pereira
Institute of Pharmacology and Experimental Therapeutics/IBILI, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal - S26-04
The role of basal ganglia in neuropsychiatric disorders
Miguel Castelo-Branco
ICNAS-P, University of Coimbra, Coimbra, Portugal
Session Abstract
Monoaminergic toxins that stretch from nanoparticles to psychostimulants are ubiquitous and pose serious mood dysregulations including depressive disosrders associated with basal ganglia dysfunction. However these emotional derangements underlying basal ganglia disorders have been overlooked. The primary goal of this workshop is to offer a molecule-to-men approach lending translational perspective to these wondrous health problems.
Herein we will discuss in vitro and in vivo data showing that environmental toxins disrupt dopaminergic pathways thus contributing to mood disorders that predate motor impairments in basal ganglia perturbations ranging from Parkinson disease to drug addiction. Presented preclinical data will set the background for clinical and epidemiological data on the role of dopamine on neuropsychiatric disorders to be offered in this workshop.
